Vaxart, Inc. - Common Stock stock is down -6.96% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.67% of the previous 50 December’s closed higher than November.
Vaxart, Inc. engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.